금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
British Pound gathers strength above 1.3550 as softer US data cools Fed hike bets
The GBP/USD pair gains traction to near 1.3555 during the early European trading hours on Monday. Th...
Hormuz Tanker Traffic Slows to a Trickle
Tanker traffic via the Strait of Hormuz slowed further over the weekend, maintaining upward pressure...
Euro rallies to two-month high, eyes 1.1600 as USD struggles amid receding Fed hike bets
The EUR/USD pair builds on last week's bounce from the vicinity of the 1.1500 psychological mark and...
Bausch + Lomb abandons glaucoma drops after phase 2 failure
IYF vs. KRE: Which Bank ETF Is the Better Buy in 2026?
These bank ETFs offer different risk/reward trade-offs for investing in the financial services sector.
Meta’s stock rebounds as agentic AI coding and custom chips ease spending fears
Shares of Meta rallied on Thursday following the launch of a new AI model and reports of a big custom-chip milestone.
Fermi falls after launching $350M convertible notes offering
Sector Update: Energy Stocks Fall Late Afternoon
Energy stocks were lower late Thursday afternoon, with the NYSE Energy Sector Index falling 1.2% and
Gas spikes, snacks tank: PepsiCo issues warning on consumer squeeze
PPA vs ARKX Aerospace ETF Showdown: Which ETF Is the High Flier for 2026?
One targets traditional defense contractors with lower costs; other pursues speculative space tech with higher volatility. Which fits your portfolio?
Ducommun downgraded at RBC on current valuation, defense outlook
Carnival stock ends weekly fall, surges 5% despite rising Middle East risks
Risky leveraged ETFs are booming in 2026. Some worry they could be making the stock market more volatile.
Some say traders who gravitate toward these products see big swings in the underlying stocks as a feature, not a bug.
Sector Update: Energy Stocks Fall Thursday Afternoon
Energy stocks were lower Thursday afternoon, with the NYSE Energy Sector Index falling 1.1% and the
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.